Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioma 2Glioblastoma 2Brain Neoplasms 2

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × trans-sodium crocetinate × Clear all
NCT03393000 2021-07-22

INTACT

Diffusion Pharmaceuticals Inc

Phase 3 Terminated
19 enrolled 8 charts
CNS

Glioblastoma

NCT01465347 2017-07-14

Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

Diffusion Pharmaceuticals Inc

Phase 1/2 Completed
59 enrolled 10 charts
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT00826930 2010-08-12

Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma

Diffusion Pharmaceuticals Inc

Phase 1 Terminated
1 enrolled
CNS

Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡